ATE551073T1 - Markierte hgf-bindende peptide für bildgebung - Google Patents

Markierte hgf-bindende peptide für bildgebung

Info

Publication number
ATE551073T1
ATE551073T1 AT08750628T AT08750628T ATE551073T1 AT E551073 T1 ATE551073 T1 AT E551073T1 AT 08750628 T AT08750628 T AT 08750628T AT 08750628 T AT08750628 T AT 08750628T AT E551073 T1 ATE551073 T1 AT E551073T1
Authority
AT
Austria
Prior art keywords
imaging
binding peptides
labelled
monitoring
vivo
Prior art date
Application number
AT08750628T
Other languages
English (en)
Inventor
Edvin Johannesen
Alan Cuthbertson
Original Assignee
Ge Healthcare As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0709441A external-priority patent/GB0709441D0/en
Priority claimed from GB0715682A external-priority patent/GB0715682D0/en
Application filed by Ge Healthcare As filed Critical Ge Healthcare As
Application granted granted Critical
Publication of ATE551073T1 publication Critical patent/ATE551073T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/0059—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence
    • A61B5/0071—Measuring for diagnostic purposes; Identification of persons using light, e.g. diagnosis by transillumination, diascopy, fluorescence by measuring fluorescence emission
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B5/00—Measuring for diagnostic purposes; Identification of persons
    • A61B5/48—Other medical applications
    • A61B5/4842—Monitoring progression or stage of a disease
AT08750628T 2007-05-16 2008-05-16 Markierte hgf-bindende peptide für bildgebung ATE551073T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0709441A GB0709441D0 (en) 2007-05-16 2007-05-16 Peptide imaging agents
GB0715682A GB0715682D0 (en) 2007-08-13 2007-08-13 Peptide imaging agents
PCT/GB2008/001696 WO2008139207A2 (en) 2007-05-16 2008-05-16 Labelled hgf binding peptides for imaging

Publications (1)

Publication Number Publication Date
ATE551073T1 true ATE551073T1 (de) 2012-04-15

Family

ID=39743846

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08750628T ATE551073T1 (de) 2007-05-16 2008-05-16 Markierte hgf-bindende peptide für bildgebung

Country Status (17)

Country Link
US (1) US8529874B2 (de)
EP (1) EP2146749B1 (de)
JP (1) JP2010526859A (de)
KR (2) KR20150017387A (de)
CN (1) CN101848734B (de)
AT (1) ATE551073T1 (de)
AU (1) AU2008249821B2 (de)
BR (1) BRPI0811210B1 (de)
CA (1) CA2685553C (de)
ES (1) ES2385066T3 (de)
IL (1) IL201778A0 (de)
MX (1) MX2009012386A (de)
NZ (1) NZ581160A (de)
PL (1) PL2146749T3 (de)
RU (2) RU2473361C9 (de)
WO (1) WO2008139207A2 (de)
ZA (1) ZA200908016B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010527922A (ja) * 2007-05-16 2010-08-19 ジーイー・ヘルスケア・アクスイェ・セルスカプ 光学造影剤
GB0718967D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0918321D0 (en) 2009-10-20 2009-12-02 Ge Healthcare As Cyclic peptide synthesis
JP2013534557A (ja) * 2010-06-29 2013-09-05 ジーイー・ヘルスケア・アクスイェ・セルスカプ 色素組成物及び色素合成法
GB201010878D0 (en) 2010-06-29 2010-08-11 Ge Healthcare As Dye compositiion and dye syntheses
GB201013808D0 (en) * 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
EP2625281A2 (de) * 2010-10-06 2013-08-14 EMD Millipore Corporation Cyaninverbindungen, konjugate daraus und verfahren zu ihrer verwendung
WO2012118909A1 (en) 2011-03-01 2012-09-07 Ge Healthcare Limited Radiolabelled octreotate analogues as pet tracers
GB201103696D0 (en) 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
DE102011118029A1 (de) * 2011-06-20 2012-12-20 Universität Leipzig Modifizierte antibiotische Peptide mit variabler systemischer Freisetzung
GB201116733D0 (en) 2011-09-28 2011-11-09 Ge Healthcare As Peptide margin imaging agents
GB201116862D0 (en) 2011-09-30 2011-11-09 Ge Healthcare As Infusion imaging method
GB201121914D0 (en) * 2011-12-20 2012-02-01 Ge Healthcare Ltd Method for patient selection
US10046068B2 (en) * 2013-03-15 2018-08-14 Arizona Board Of Regents On Behalf Of Arizona State University Saccharide conjugates
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
CN105111773B (zh) * 2015-08-19 2017-06-27 大连理工大学 一类氨基菁类荧光染料及其制备方法和应用
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
CN112129736B (zh) * 2020-09-22 2022-08-02 四川大学华西医院 粘蛋白和循环肿瘤细胞的均相可视化/荧光poct检测方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039894A2 (en) 2002-05-10 2004-05-13 Carnegie Mellon University Chiral indole intermediates and their fluorescent cyanine dyes containing functional groups
GB0223249D0 (en) * 2002-10-08 2002-11-13 Amersham Plc Improved imaging agents
AU2004214420A1 (en) * 2003-02-19 2004-09-02 Sicel Technologies Inc. In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes
WO2004078778A2 (en) * 2003-03-03 2004-09-16 Dyax Corp. PEPTIDES THAT SPECIFICALLY BIND HGF RECEPTOR (cMet) AND USES THEREOF
NO20034350D0 (no) * 2003-09-29 2003-09-29 Amersham Health As Optisk avbilding av kolorektal kreft
US7750163B2 (en) * 2003-10-31 2010-07-06 GE Healthcare U.K. Limited Cyanine dye labelling reagents
JP2007510643A (ja) 2003-11-06 2007-04-26 ジーイー・ヘルスケア・アクスイェ・セルスカプ 医薬化合物
NO20035682D0 (no) 2003-12-18 2003-12-18 Amersham Health As Optisk avbildning av ösofagkreft og Barretts ösofag
WO2006073314A1 (en) * 2005-01-06 2006-07-13 Ge Healthcare As Optical imaging
WO2006078914A1 (en) * 2005-01-21 2006-07-27 Washington University In St. Louis Compounds having rd targeting motifs
GB0502277D0 (en) 2005-02-04 2005-03-09 Amersham Plc Novel imaging agents
ATE502048T1 (de) * 2005-04-22 2011-04-15 Univ Washington Fluoreszentes chlorotoxinkonjugat und verfahren zur intraoperativen sichtbarmachung von krebs
NO20053354D0 (no) * 2005-07-11 2005-07-11 Amersham Health As Optical imaging contrast agent.

Also Published As

Publication number Publication date
NZ581160A (en) 2012-05-25
AU2008249821B2 (en) 2013-08-22
CA2685553C (en) 2017-03-28
CA2685553A1 (en) 2008-11-20
BRPI0811210B1 (pt) 2021-11-09
RU2473361C2 (ru) 2013-01-27
US20100150843A1 (en) 2010-06-17
RU2009140475A (ru) 2011-06-27
KR101578225B1 (ko) 2015-12-17
WO2008139207A2 (en) 2008-11-20
RU2009140478A (ru) 2011-06-27
US8529874B2 (en) 2013-09-10
CN101848734A (zh) 2010-09-29
BRPI0811210A2 (pt) 2014-11-11
PL2146749T3 (pl) 2012-09-28
IL201778A0 (en) 2010-06-16
EP2146749B1 (de) 2012-03-28
JP2010526859A (ja) 2010-08-05
KR20150017387A (ko) 2015-02-16
RU2473361C9 (ru) 2013-06-20
CN101848734B (zh) 2013-08-28
KR20100016543A (ko) 2010-02-12
AU2008249821A1 (en) 2008-11-20
RU2475266C2 (ru) 2013-02-20
ZA200908016B (en) 2012-04-25
ES2385066T3 (es) 2012-07-17
MX2009012386A (es) 2009-12-03
EP2146749A2 (de) 2010-01-27
WO2008139207A3 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
ATE551073T1 (de) Markierte hgf-bindende peptide für bildgebung
GB0718967D0 (en) Peptide imaging agents
MX2012014739A (es) Novedoso anticuerpo para el diagnostico y/o pronostico de cancer.
MX2012002139A (es) Anticuerpo anti-cmet y su uso para la deteccion y diagnostico del cancer.
WO2011015602A3 (en) Lung cancer biomarkers
WO2010017515A3 (en) Breast cancer specific markers and methods of use
EA200802242A1 (ru) Способ определения того, будет или не будет пациент респондером на иммунотерапию
WO2009085216A3 (en) Compositions and methods for detecting or elimninating senescent cells to diagnose or treat disease
WO2012097313A3 (en) Therapeutic antibodies against ror-1 protein and methods for use of same
WO2008104803A3 (en) Proteins
MX2011006422A (es) Autoanticuerpos humanos anti-alfa-sinucleina.
BR112015014751A2 (pt) anticorpos anti-tau humanos
EA201791876A1 (ru) Моноклональные антитела к прогастрину и их применение
WO2009090553A3 (en) Compositions and methods of detecting post-stop peptides
MX345092B (es) Anticuerpos anti-tau humanos,.
WO2010059969A3 (en) Use of anti-vegf antibody in combination with chemtherapy for treating breast cancer
WO2005044990A3 (en) Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2008073899A3 (en) Prrg4-associated compositions and methods of use thereof in methods of tumor diagnosis
GEP201706737B (en) Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2010132370A3 (en) Soluble tlt-1 for the treatment and diagnosis of sepsis
CY1120063T1 (el) Αντισωματα κατα του ανθρωπινου dlk-1 που εχει δραση κατα των ογκων in vivo
BR112013021056A2 (pt) anticorpo monoclonal, linhagem de células de hibridoma, kit para diagnóstico, métodos para a produção de um anticorpo monoclonal e de um agente de ligação, agente de ligação sequência de aminoácidos purificada, método para a obtenção de uma sequência do ácido nucleico codificante, molécula do ácido nucleico isolado codificante, vetor, célula hospedeira isolada, proteína de fusão, método de triagem para a presença de uma doença, de uma condição, métodos de diagnóstico de um indivíduo, de prognóstico para um indivíduo, e de monitoramento de um indivúdo, e, método para detecção da presença ou ausência de um câncer cervical
WO2012166700A3 (en) Molecular profiling of a lethal tumor microenvironment
EA201100253A1 (ru) Глутаминилциклаза в качестве диагностического/прогностического индикатора нейродегенеративных заболеваний